Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Vaccitech (VACC) shares

Learn how to easily invest in Vaccitech shares.

Vaccitech is a biotechnology business based in the US. Vaccitech stocks (VACC.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $14.52 – a decrease of 7.34% over the previous week. Vaccitech employs 48 staff and has a trailing 12-month revenue of around $622,257.

How to buy shares in Vaccitech

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – VACC – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Vaccitech stock price (NASDAQ:VACC)

Use our graph to track the performance of VACC stocks over time.

Vaccitech shares at a glance

Information last updated 2022-01-19.
Latest market close$9.22
52-week range$7.50 - $17.99
50-day moving average $11.44
200-day moving average $13.97
Wall St. target price$24.00
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-4.16

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Offer
FREE TRADES
Wealthsimple Trade
Finder Rating:
★★★★★
3.9 / 5
$0
$0
Stocks, ETFs
Get 2 free stocks when you deposit and trade $150.
Scotia iTRADE
Finder Rating:
★★★★★
3.8 / 5
$4.99 - $9.99
$0
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
Interactive Brokers
Finder Rating:
★★★★★
4.1 / 5
Min. $1.00, Max. 0.5%
$0
Stocks, Bonds, Options, ETFs, Currencies, Futures
OFFER
CIBC Investor's Edge
Finder Rating:
★★★★★
4 / 5
$4.95 - $6.95
$0 if conditions met, otherwise $100/year
Stocks, Bonds, Options, Mutual Funds, ETFs
Get up to $2,000 cash back. Conditions apply. Offer ends March 1, 2022.
Questrade
Finder Rating:
★★★★★
4.2 / 5
$4.95 - $9.95
$0
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
Qtrade Direct Investing
Finder Rating:
★★★★★
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get a $50 bonus when you open a new RRSP, TFSA or RESP and start pre-authorized contributions of $200+/month. Valid until March 1, 2022.
loading

Compare up to 4 providers

Online stock trading

Is it a good time to buy Vaccitech stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Vaccitech price performance over time

Historical closes compared with the close of $9.22 from 2022-01-21

1 week (2022-01-14) -7.34%
1 month (2021-12-23) -3.76%
3 months (2021-10-22) -35.34%
6 months (2021-07-23) -37.19%
1 year (2021-01-19) N/A
2 years (2020-01-19) N/A
3 years (2019-01-19) N/A
5 years (2017-01-19) N/A

Vaccitech financials

Revenue TTM $622,257
Gross profit TTM $-9,566,249
Return on assets TTM -30.07%
Return on equity TTM -420.06%
Profit margin 0%
Book value $7.05
Market capitalisation $348.1 million

TTM: trailing 12 months

Vaccitech share dividends

We're not expecting Vaccitech to pay a dividend over the next 12 months.

Vaccitech overview

Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel T cell immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancers. Its therapeutic programs include VTP-300 for the treatment of chronic hepatitis B infection; VTP-200 for the treatment of human papilloma virus infection; VTP-850 indicated for the treatment of prostate cancer; and VTP-600 for the treatment of non-small cell lung cancer. The company's prophylactic programs include VTP-400 for the prevention of herpes zoster or shingles; and VTP-500 for the prevention of Middle East respiratory syndrome. In addition, it is developing a COVID-19 vaccine with the University of Oxford, which is approved for use in various territories and licensed worldwide to AstraZeneca through Oxford University Innovation. The company was formerly known as Vaccitech Rx Limited and changed its name to Vaccitech plc in March 2021. Vaccitech plc was founded in 2016 and is headquartered in Oxford, the United Kingdom. .

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Ask an Expert

You must be logged in to post a comment.

Go to site